|
|
||||||||
Ann Thorac Surg 1999;68:1252-1256
© 1999 The Society of Thoracic Surgeons
a Second Department of Surgery, Osaka City University Medical School, Osaka, Japan
Address reprint requests to Dr Kumano, Second Department of Surgery, Osaka City University Medical School, 1-5-7 Asahimachi, Abeno-ku, Osaka 545-0051, Japan
Background. We examined the safety of reduced systemic heparinization during heparin-coated cardiopulmonary bypass by measuring coagulofibrinolitic indices, including fibrinopeptide A, which directly reflects fibrinogenesis.
Methods. Twenty-four patients who had elective cardiac operations were perfused using a circuit coated with covalently bonded heparin. Twelve patients received 300 U/kg of heparin and the remaining 12 patients received 150 U/kg. Blood was obtained for the measurement of thrombin-antithrombin III complexes, fibrinopeptide A, plasmin-alpha 2 plasmin inhibitor complexes, and D-dimer preoperatively; after heparin administration; 10, 60, and 90 minutes after the start of bypass; after protamine administration; and 1, 3, 6, 12, and 24 hours after the end of bypass.
Results. Preoperative, intraoperative, and postoperative variables including postoperative bleeding were not significantly different between the two groups. Further, there were no complications in either group. No significant differences between the two groups were noted for any hematologic index at any time point.
Conclusions. Reduced systemic heparinization combined with a heparin-coated cardiopulmonary bypass circuit is biochemically and clinically safe but does not reduce postoperative bleeding.
This article has been cited by other articles:
![]() |
R. D. Frank, U. Muller, R. Lanzmich, C. Groeger, and J. Floege Anticoagulant-free Genius(R) haemodialysis using low molecular weight heparin-coated circuits Nephrol. Dial. Transplant., April 1, 2006; 21(4): 1013 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fujii, S. Suehiro, H. Kumano, T. Shibata, K. Hattori, H. Hirai, and T. Aoyama Relationship between granulocyte elastase and C3a under protamine dosing in on-pump cardiac surgery Eur J Cardiothorac Surg, September 1, 2005; 28(3): 431 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ikuta, H. Fujii, T. Shibata, K. Hattori, H. Hirai, H. Kumano, and S. Suehiro A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy Ann. Thorac. Surg., May 1, 2004; 77(5): 1678 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shibata, Y. Sasaki, K. Hattori, H. Hirai, M. Hosono, H. Fujii, and S. Suehiro Sonoclot analysis in cardiac surgery in dialysis-dependent patients Ann. Thorac. Surg., January 1, 2004; 77(1): 220 - 225. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Johnell, G. Elgue, R. Larsson, A. Larsson, S. Thelin, and A. Siegbahn Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 321 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Paparella, T. M. Yau, and E. Young Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update Eur J Cardiothorac Surg, February 1, 2002; 21(2): 232 - 244. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |